Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B
Tarih
2016Yazar
Hatemi, Ibrahim
Durcan, Emre
Atay, Kadri
Tuncer, Murat
Koroglu, Emine
Canbakan, Billur
Yurttas, Berna
Gultepe, Ilhami
Ozdemir, Sebati
Sonsuz, Abdullah
Üst veri
Tüm öğe kaydını gösterÖzet
Background/Aims: Several guidelines recommend the use of tenofovir or entecavir as the first-line treatment for hepatitis B due to the lower resistance rates of these drugs than lamivudine, although lamivudine may still be preferred because of its low adverse effect profile and cost. It is important to know which patients might benefit from lamivudine as the first-line treatment. We aimed to assess the success rates of lamivudine, entecavir, and tenofovir, as well as the resistance rates, frequencies of HBsAg clearance, and risk factors for lamivudine resistance.
Koleksiyonlar
- Makale [92796]